67625-36-9

Usage

Uses

Used in Organic Synthesis:
5-Chloroimidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester is used as a building block or reagent in various chemical reactions for the synthesis of complex organic molecules. Its reactivity and available functional groups make it a versatile compound in the field of organic chemistry.
Used in Pharmaceutical Industry:
5-Chloroimidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester is used as a potential precursor in the development of new pharmaceutical compounds. Its unique structure and reactivity may contribute to the creation of novel drug candidates with potential therapeutic applications.
Used in Chemical Research:
5-Chloroimidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester is used as a research tool in academic and industrial laboratories to study its chemical properties, reactivity, and potential applications in various chemical processes.
Used in Material Science:
5-Chloroimidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester is used as a component in the development of new materials with specific properties, such as improved stability, reactivity, or selectivity in various applications.

Upstream product

• 45644-21-1 6-chloropyridin-2-amine 
• 70-23-5 ethyl Bromopyruvate 

Downstream Products

• 907945-75-9 ethyl 5-(4-chlorophenyl)imidazo[1,2-a]pyridine-2-carboxylate 
• 1000017-93-5 5-chloro-imidazo[1,2-a]pyridine-2-carboxylic acid 

Relevant academic research and scientific papers

SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS

The present invention provides fused derivatives of Formula (I) that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PBKs including, for example, inflammatory disorders, immune- based disorders, cancer, and other diseases.

SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS beta-SECRETASE INHIBITORS

The present invention is directed to substituted imidazo[1,2-a]pyridine derivatives, pharmaceutically acceptable salts thereof, and tautomers of such compounds or salts, that inhibit beta-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which BACE is involved.

Discovery of piperazinylimidazo[1,2-a]pyridines as novel S4 binding elements for orally active Factor Xa inhibitors

We have recently reported the discovery of orally active sulfonylalkylamide Factor Xa (FXa) inhibitors, as typified by compound 1 (FXa IC50 = 0.061 μM). Since the pyridylpiperidine moiety was not investigated in our previous study, we conducted detailed structure-activity relationship studies on this S4 binding element. This investigation led to the discovery of piperazinylimidazo[1,2-a]pyridine 2b as a novel and potent FXa inhibitor (FXa IC50 = 0.021 μM). Further modification resulted in the discovery of 2-hydroxymethylimidazo[1,2-a]pyridine 2e (FXa IC50 = 0.0090 μM), which was found to be a selective and orally bioavailable FXa inhibitor with reduced CYP3A4 inhibition.

AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR

The present invention provides a GPR receptor function regulator comprising the compound represented by the formula: [wherein ring A is an optionally substituted isocyclic or heterocyclic ring, P is a bond or spacer, ring D is an optionally substituted monocyclic aromatic ring which may be condensed with a 5-to 7-membered ring, V is a bond or the group represented by the formula -CR14=CR15 - or - N=CR16- (wherein R14, R15 and R16 each represents a hydrogen atom or optionally substituted hydrocarbon group), Q is a bond or spacer, and W is a carboxyl or a group biologically equivalent to a carboxyl] or its salt or a prodrug thereof